Infectious Complications in Biologic and Targeted Therapies

ISBN-13: 9783031113659 / Angielski / Miękka / 2023

Opis

This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients.

This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.

Spis treści

Chapter No Chapter Title as per TOC Part I Overview of the epidemiology, risk and prevention of infections. 1 Overview on the risk of infection associated with biologic and target therapies 2 Timeline and Infectious disease evaluation of candidates to new therapies 3 Safety and Efficacy of Vaccines in patients on Targeted and Biologic therapies.  4 Travel and risk of infections Part II Specific agents and risk of infections 5 Anti-tumor necrosis factor-alpha agents 6 CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 7 CD19, CD20 and CD52 8 Cell-surface receptors: EGFR and VEGFR-targeted agents 9 Interleukin-1 targeted agents 10 Interleukin-6 targeted agents 11 Interleukin-12 and -23 targeted agents 12 Sphingosine-1 phosphate receptor modulators 13 Immune checkpoint inhibitors 14 α4-integrin (and other leukocyte integrin) targeting agents 15 Tyrosin-kinase inhibitors 16 Bcl-2, JAK and mTOR inhibitors 17 Infection associated with the use of CAR T-cells Part III Clinical conditions associated with the use of biologic and targeted therapies 18 Pulmonary infiltrates 19 Tuberculosis 20 Cytomegalovirus and other herpesviruses 21 Invasive fungal disease 22 Progressive multifocal leukoencephalopathy 23 Hepatitis Viruses 24 Immune-targeted therapies for COVID-19

O autorze

Carlos Cervera, MD, PhD

Division of Infectious Diseases, Department of Medicine. 

University of Alberta.

1-124F Clinical Sciences Building. 11350 83 Ave. 

Edmonton T6G 2G3

Alberta, Canada

Primary email address: cerveraa@ualberta.ca

Jose Maria Aguado, MD, PhD

Unit of Infectious Diseases, 

Research Institute Hospital "12 de Octubre" (i + 12),

University Hospital “12 de Octubre”, 

Complutense University of Madrid

Madrid, Spain

Primary email address: jaguadog1@gmail.com